Greenland Mines Q2 Loss Narrows but Going Concern and Nasdaq Delisting Risks Persist
GRML sits 27% above its 52-week low of $0.156.
Summary
Greenland Mines' Q2 loss narrowed but the company still faces going concern doubts, a Nasdaq delisting deadline, and the loss of its ATM funding source.
Key Events · Earnings and Guidance · GRML
-
Q2 Net Loss Narrows
Net loss of $3.69 million for Q2 2026, down from $4.09 million in Q2 2025, but six-month loss of $17.54 million is nearly triple the prior year's $6.33 million.
-
Going Concern Warning Reiterated
Management states substantial doubt about the company's ability to continue as a going concern, with only $9.34 million in cash and an accumulated deficit of $38.7 million.
-
Nasdaq Delisting Risk
The company has until September 14, 2026 to regain compliance with the $1.00 minimum bid price rule; its stock closed at $0.26 on June 30, 2026.
-
ATM Facility Terminated
The At-the-Market Sales Agreement with A.G.P. was terminated effective July 4, 2026, removing a source of equity financing.
Analysis · GRML · Life Sciences
Greenland Mines reported a Q2 net loss of $3.69 million, an improvement from $4.09 million a year ago, but the six-month loss ballooned to $17.54 million. The company reiterated substantial doubt about its ability to continue as a going concern, with only $9.34 million in cash. It also faces a September 14, 2026 deadline to regain Nasdaq compliance or risk delisting. The termination of its ATM facility removes a key funding source, and the adoption of a poison pill suggests defensive maneuvering. These factors create significant uncertainty for shareholders.
How filings like this one have moved
In the 30 days to Oct 25, 2026, 37% of the 945 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.78%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRML was trading at $0.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.5M. The 52-week trading range was $0.16 to $0.95. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.